Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.60 |
| ▸ | EDNRB | P24530 | 2/20 | 0.51 |
| ▸ | EDNRA | P25101 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164065 | 0.85 | S1PR1 (0.60) | S1PR1EDNRBEDNRAKMT2AMEN1 | |
| SCHEMBL4159021 | 0.79 | S1PR1 (0.56) | S1PR1EDNRBEDNRAMMP2 | |
| SCHEMBL4169726 | 0.75 | S1PR1 (1.00) | S1PR1KMT2A | |
| SCHEMBL3889414 | 0.74 | S1PR1 (0.77) | S1PR1KMT2A | |
| SCHEMBL3885555 | 0.74 | S1PR1 (0.53) | S1PR1EDNRBEDNRAKMT2AMEN1 | |
| SCHEMBL3892610 | 0.72 | S1PR1 (0.72) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL3887084 | 0.70 | S1PR1 (0.69) | S1PR1KMT2A | |
| SCHEMBL13875332 | 0.69 | S1PR1 (0.60) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL13875328 | 0.69 | S1PR1 (0.58) | S1PR1MMP2 | |
| SCHEMBL7909439 | 0.69 | CA2 (0.61) | MMP2MMP1MMP3MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007129019-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ADGRE5, ADGRF1, SELPLG | S1PR1 677/4885EDNRB 5/4885EDNRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.